The above considering, a dual-faceted effect of IL-33, (i.e., being beneficial to hepatic steatosis, mainly through its action in the adipose tissue, but adverse to hepatic fibrosis), cannot be excluded. The gene discussed is IL33; the disease is Hepatic fibrosis.